ADXN vs. AEZS, ATHE, CMMB, GRTX, GHSI, MTEM, ERNA, GRAY, ABVC, and MIRA
Should you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Aeterna Zentaris (AEZS), Alterity Therapeutics (ATHE), Chemomab Therapeutics (CMMB), Galera Therapeutics (GRTX), Guardion Health Sciences (GHSI), Molecular Templates (MTEM), Eterna Therapeutics (ERNA), Graybug Vision (GRAY), ABVC BioPharma (ABVC), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.
Addex Therapeutics (NASDAQ:ADXN) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk, community ranking and dividends.
Aeterna Zentaris has a net margin of -368.01% compared to Addex Therapeutics' net margin of -644.66%. Aeterna Zentaris' return on equity of -63.20% beat Addex Therapeutics' return on equity.
Addex Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.
Addex Therapeutics has higher earnings, but lower revenue than Aeterna Zentaris. Aeterna Zentaris is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aeterna Zentaris received 407 more outperform votes than Addex Therapeutics when rated by MarketBeat users. Likewise, 62.35% of users gave Aeterna Zentaris an outperform vote while only 46.15% of users gave Addex Therapeutics an outperform vote.
Aeterna Zentaris has a consensus target price of $60.00, indicating a potential upside of 614.29%. Given Aeterna Zentaris' stronger consensus rating and higher probable upside, analysts plainly believe Aeterna Zentaris is more favorable than Addex Therapeutics.
In the previous week, Aeterna Zentaris had 2 more articles in the media than Addex Therapeutics. MarketBeat recorded 6 mentions for Aeterna Zentaris and 4 mentions for Addex Therapeutics. Aeterna Zentaris' average media sentiment score of 1.14 beat Addex Therapeutics' score of 0.69 indicating that Aeterna Zentaris is being referred to more favorably in the news media.
16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 0.1% of Aeterna Zentaris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Aeterna Zentaris beats Addex Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Addex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Addex Therapeutics Competitors List
Related Companies and Tools
